Effects of Anti-Seizure Medication on Neuregulin-1 Gene and Protein in Patients with First-Episode Focal Epilepsy
Xin Zhao,Guijiang Huang,Zhenrong Xie,Yaxiong Mo,Hongxuan Zhu,Yajie Gao,Yanbing Han,Wei Tang
DOI: https://doi.org/10.2147/ndt.s438942
IF: 2.989
2024-04-08
Neuropsychiatric Disease and Treatment
Abstract:Xin Zhao, 1, 2 Guijiang Huang, 2 Zhenrong Xie, 2 Yaxiong Mo, 3 Hongxuan Zhu, 2 Yajie Gao, 2 Yanbing Han, 4 Wei Tang 2 1 Department of Pharmacy, The Third Affiliated Hospital of Inner Mongolia Medical University, Baotou, People's Republic of China; 2 Department of Science and Education, The First Affiliated Hospital of Kunming Medical University, Kunming, People's Republic of China; 3 Department of Pediatrics, The First Affiliated Hospital of Kunming Medical University, Kunming, People's Republic of China; 4 Department of Neurology, The First Affiliated Hospital of Kunming Medical University, Kunming, People's Republic of China Correspondence: Wei Tang, Department of Science and Education, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan Province, People's Republic of China, Email Yanbing Han, Department of Neurology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan Province, People's Republic of China, Email Introduction: Neuregulin-1 (NRG-1) appears to play a role in the pathogenesis of several neuropsychiatric disorders, including epilepsy. We conducted a study to investigate the effect of anti-seizure medication on NRG-1 mRNA and NRG-1 protein levels in patients with first-episode focal epilepsy. Methods: The levels of NRG-1 mRNA isoforms (type I, II, III, and IV) in peripheral blood mononuclear cells (PBMCs) of 39 healthy controls, 39 first-episode focal epilepsy patients before anti-seizure medication (ASM) therapy and four weeks after administration of ASM were measured by RT-qPCR, and the levels of NRG-1 protein in the serum of samples of each group were determined using ELISA. In addition the relationship between efficacy, NRG-1 mRNA expression, and NRG-1 protein expression was analyzed. Results: The levels of NRG-1 mRNA progressively increased in patients with first-episode focal epilepsy treated with ASM and were distinctly different from those before medication, but remained lower than in healthy controls (all P < 0.001). Before and after drug administration, NRG-1 protein levels were substantially higher in epileptic patients than in healthy controls, and no significant changes were detected with prolonged follow-up ( P < 0.001). Patients with epilepsy who utilized ASM were able to control seizures with an overall efficacy of 97.4%. There was a negative correlation between NRG-1 mRNA levels and efficacy: as NRG-1 mRNA levels increased, seizures reduced (all P < 0.05). Conclusion: Our research indicated that NRG-1 may play a role in the pathophysiology of epilepsy. NRG-1 mRNA may provide ideas for the discovery of novel epilepsy therapeutic markers and therapeutic targets for novel ASM. Keywords: neuregulin-1, focal epilepsy, drug treatment, pathophysiology Epilepsy is a severe, chronic neurological disorder that affects approximately 50 million individuals worldwide. 1,2 There are several manifestations of epilepsy, 3 of which focal epilepsy represents 60%. The pathogenesis of epilepsy is not yet completely elucidated. The imbalance of neural excitation and inhibition, which is the imbalance of glutamate (Glu) and γ-aminobutyric acid (GABA) neurotransmission, is one of the hypotheses for the pathogenesis of epilepsy. 4 The role of genetic factors as endogenous factors in the pathogenesis of epilepsy is gaining increasing attention. 5 Exploration of genes associated with epilepsy may be instrumental in elucidating the pathogenesis of epilepsy. Seizures seriously damaged the physical and mental health of patients, diminishing their quality of life and placing tremendous stress on epilepsy patients' families. 3,6 Although a variety of anti-seizure medication (ASM) is available, many have similar efficacy and it is not possible to predict which drug is best for a given patient. Furthermore, only a few biomarkers can reliably forecast treatment response or the risk of epilepsy drug resistance. 7 Effective prevention and treatment of epilepsy is therefore a current clinical priority, and it is essential to seek potential therapeutic markers, identify therapeutic targets for novel ASM, and develop novel drug candidates. Neuregulin (NRG) is a family of growth factors that transmits signals via ErbB family receptors. Neuregulin-1 (NRG-1) is located on chromosome 8p and is the most extensively researched member of its family. 8 Notably, chromosome 8 has been one of the more problematic chromosomes in terms of rearrangements and translocations, 9 which may be one cause for its association with certain diseases. NRG-1 is div -Abstract Truncated-
psychiatry,clinical neurology